Theratechnologies to be Acquired by CB Biotechnology
Deal News | Jul 03, 2025 | Globenewswire
Theratechnologies, a publicly traded biopharmaceutical company, is set to be acquired by CB Biotechnology, an affiliate of Future Pak, for $3.01 per share in cash, with an additional conditional value right (CVR) that could total up to $1.19 per share based on performance milestones. This totals a potential $254 million transaction, representing a 126% premium over Theratechnologies' closing price on NASDAQ prior to the announcement, and 216% considering the maximum CVR payment. The acquisition follows a rigorous sales process led by a special committee of Theratechnologies' board. Future Pak, a long-established firm in pharmaceutical manufacturing and distribution, sees this acquisition as a strategic milestone that will enhance their portfolio and market reach. The deal is set to conclude by the end of November 2025, pending shareholder and court approval. The transaction will transform Theratechnologies into a private entity, delisting from TSX and NASDAQ. The financing for this acquisition will involve cash and a loan facility secured by Future Pak.
Sectors
- Biopharmaceuticals
- Pharmaceutical Manufacturing
Geography
- Canada – Theratechnologies is based in Montreal, Quebec, making Canada a significant geographical location in the article.
- United States – Future Pak is headquartered in Wixom, Michigan, making the US another key geographical focus.
Industry
- Biopharmaceuticals – Theratechnologies operates in this sector, focusing on developing and marketing innovative treatments.
- Pharmaceutical Manufacturing – Future Pak is involved in manufacturing pharmaceutical products, which links the acquisition to this industry.
Financials
- 254,000,000 – Total transaction value assuming full CVR payment.
- 3.01 – Offer price per share in cash for Theratechnologies stock.
- 1.19 – Potential additional payment per share as conditional value rights (CVR) based on performance milestones.
- 220,000,000 – Credit facility provided by Future Pak's lenders to finance the acquisition.
- 6,000,000 – Termination fees that may be payable to CB Biotechnology if the acquisition is not completed.
- 12,000,000 – Break fee that Future Pak must pay if the transaction does not proceed under certain conditions.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Theratechnologies Inc. | Target company | Company | A biopharmaceutical company focused on developing innovative treatments. |
| CB Biotechnology, LLC | Bidding Company/Buyer | Company | An affiliate of Future Pak, involved in the acquisition of Theratechnologies. |
| Future Pak, LLC | Parent Company of Buyer | Company | A company engaged in pharmaceutical manufacturing and distribution. |
| Barclays Capital Inc. | Financial advisor | Company | Exclusive financial advisor to Theratechnologies and its special committee. |
| Raymond James Ltd. | Independent financial advisor | Company | Provided independent financial advisory services to Theratechnologies' special committee. |
| Fasken Martineau DuMoulin LLP | Legal advisor | Company | Legal advisor to Theratechnologies and its special committee. |
| Norton Rose Fulbright Canada LLP | Independent legal advisor | Company | Independent legal advisor to Theratechnologies' special committee. |
| Bourne Partners Securities | Financial advisor | Company | Exclusive financial advisor to Future Pak. |
| Honigman LLP | Legal advisor | Company | Legal advisor to Future Pak. |
| McMillan LLP | Legal advisor | Company | Legal advisor to Future Pak. |
| DPO&Co | Advisory services provider | Company | Provided advisory services to Future Pak in relation to the transaction. |